# Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults

> **NCT00820846** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 299 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** pGA2/JS7 DNA vaccine
- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** MVA/HIV62 vaccine

## Key facts

- **NCT ID:** NCT00820846
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2012-08
- **Final completion:** 2014-09
- **Target enrollment:** 299 (ACTUAL)
- **Last updated:** 2022-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00820846

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00820846, "Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00820846. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*